BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and AstraZeneca (NYSE:AZN) are among those companies with late stage drugs in trials that specifically target genetic mutations. Both BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s BMN-673, which is in phase 3 trials, and Astra’s Olaparib, which may get the EU’s go-ahead in ovarian cancer this year, address a mutation of the BRCA 1 and BRCA 2 gene that is often associated with breast and ovarian cancer. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stock performance was -5.91% in last session and finished the day at $73.93. Traded volume was 3.47million shares in the last session and the average volume of the stock remained 1.23million shares. The beta of the stock remained 0.79. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) insider ownership is 0.40%.

In a recent pipeline update, Celldex Therapeutics Inc (NASDAQ: CLDX) quietly reported that it had discontinued a pilot clinical study of CDX-1135, a drug in development for dense deposit disease (DDD), an ultra-rare orphan indication. A grand total of one patient had been enrolled since last July, and that patient did not experience sustained improvement in terms of stopping or reversing the kidney deterioration caused by the disease. Celldex Therapeutics, Inc. (NASDAQ:CLDX) dropped -9.54 percent to $21.52 Friday on volume of 3.84million shares. The intra-day range of the stock was $21.32 to $23.90. Celldex Therapeutics, Inc. (NASDAQ:CLDX) has a market capitalization of $1.92billion.

Novavax Inc. (NASDAQ:NVAX) major shareholder Pharmaceuticals Ltd Cadila sold 3,000,000 shares of Novavax Inc. (NASDAQ:NVAX) stock on the open market in a transaction dated Friday, March 21st. Novavax, Inc. (NASDAQ:NVAX)’s stock on Mar 21, 2014 reported a decrease of -5.65% to the closing price of $4.68. Its fifty two weeks range is $1.68-$6.95. The total market capitalization recorded $978.39million. The overall volume in the last trading session was 10.92million shares. In its share capital, NVAX has 168.54million outstanding shares.

Large-cap Biogen Idec Inc (NASDAQ: BIIB)’s stock has nearly doubled over the past year. Biogen Idec Inc (NASDAQ: BIIB)’s launch of multiple sclerosis drug Tecfidera powered the stock to a tremendous 2013. The drug’s recent approval in Europe should help the company continue its successful streak. On Friday, shares of Biogen Idec Inc (NASDAQ:BIIB) dropped -8.22% to close the day at $318.53. Company return on investment (ROI) is 20.70% and its monthly performance is recorded as -4.95%. Biogen Idec Inc (NASDAQ:BIIB) quarterly revenue growth is 13.50%.